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ORIGINAL ARTICLE

Duchenne Muscular Dystrophy:
Canadian Paediatric Neuromuscular
Physicians Survey

Hugh J. McMillan, Craig Campbell, Jean K. Mah, on behalf of the Canadian
Paediatric Neuromuscular Group
ABSTRACT: Background: Duchenne muscular dystrophy (DMD) is the most common form of muscular dystrophy in childhood.
Method: To assess the current care of paediatric DMD patients in Canada, a questionnaire was mailed to 17 physicians who were
members of the Canadian paediatric neuromuscular group. Areas of enquiry included; 1) multidisciplinary team composition; 2) means
of DMD diagnosis; 3) corticosteroid use; surveillance and management for: 4) orthopaedic, 5) respiratory and 6) cardiac complications
and 7) health maintenance (nutrition & immunizations). Results: Completed surveys were returned by 14/17 (82%) of physicians.
Twelve respondents followed DMD patients. All centres had multidisciplinary teams, including respirology (11/12), child neurology or
physiatry (11), physiotherapy (9), occupational therapy (9) and orthopaedic surgery (7). Deflazacort 0.9mg/kg/d was used at all centres,
which was continued after loss of independent ambulation (11), along with routine calcium and vitamin D supplementation (10). Night
splints were prescribed at all centres. Routine surveillance studies included pulmonary function testing (11), sleep studies (10),
EKG/echocardiogram (10), bone density (DEXA) scans (10), spine radiography (9), and dietician referral (4). Conclusion: Paediatric
DMD patients are receiving relatively consistent care in multidisciplinary clinics across Canada, in accordance with recommended
guidelines for DMD.
RÉSUMÉ: Dystrophie musculaire de Duchenne : enquête auprès des pédiatres du Canadian Paediatric Neuromuscular Goup. Contexte : La
dystrophie musculaire de Duchenne (DMD) est la forme la plus fréquente de dystrophie musculaire dans l’enfance. Méthode : Nous avons posté un
questionnaire à 17 médecins membres du Canadian Paediatric Neuromuscular Group afin d’évaluer les soins actuels donnés aux patients d’âge
pédiatrique atteints de DMD au Canada. L’enquête portait sur les aspects suivants : 1) la composition des équipes multidisciplinaires; 2) les moyens
diagnostiques utilisés pour poser le diagnostic de DMD; 3) l’utilisation de corticostéroïdes; la surveillance et le traitement des complications 4)
orthopédiques, 5) respiratoires et 6) cardiaques et 7) les soins de santé usuels (nutrition et immunisations). Résultats : Quatorze des 17 médecins (82%)
ont retourné le questionnaire complété. Douze d’entre eux suivaient des patients atteints de DMD. Tous les centres avaient des équipes
multidisciplinaires qui incluaient des pneumologues (11/12), des neurologues ou physiatres pédiatriques (11), des physiothérapeutes (9), des
ergothérapeutes (9) et des orthopédistes (7). Tous les centres utilisaient le déflazacort à 0,9 mg/kg/j. Cette médication était maintenue après le passage
au fauteuil roulant (11) ainsi que la prise de routine de calcium et de vitamine D (10). Des attelles nocturnes étaient prescrites dans tous les centres. La
surveillance de routine comprenait des épreuves de fonction pulmonaire (11), des études du sommeil (10), un EKG/échocardiogramme (10), mesure de
la densité osseuse (DEXA) (10), radiographie de la colonne vertébrale (9) et consultation en diététique (4). Conclusion : Les patients pédiatriques
atteints de DMD reçoivent des soins relativement uniformes dans toutes les cliniques multidisciplinaires au Canada, conformément aux
recommandations énoncées dans les lignes directrices sur la prise en charge de la DMD.

Can. J. Neurol. Sci. 2010; 37: 195-205

Duchenne muscular dystrophy (DMD) is caused by a
mutation in the DMD gene, coding for dystrophin at Xp21.
Inadequate or defective dystrophin protein causes increased
muscle membrane fragility, resulting in proximal muscle
weakness and marked elevation of serum creatine kinase (CK)
levels. Boys with DMD typically present with gait abnormalities
(toe-walking, frequent falls, delayed walking, exercise
intolerance) between ages 3 - 5 years old, with progressive loss
of independent ambulation occurring around 7 - 12 years-of-age.
Most boys live until their late 20’s, with death resulting from
respiratory or cardiac complications. Corticosteroid therapy
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offers benefit to DMD boys by improving muscle strength and
functional test scores1-4 , prolonging independent ambulation5-9,
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improving pulmonary function tests1,2, and delaying the onset of
cardiomyopathy10-12 and scoliosis13,14.
Due to the progressive nature of DMD, affected individuals
require regular monitoring and management of several areas: 1)
muscle strength and function; 2) corticosteroid treatment and
potential side-effects1,15; 3) orthopaedic issues such as soft-tissue
contractures, fractures or scoliosis; 4) respiratory complications
such as impaired secretion clearance or alveolar hypoventilation;
5) cardiomyopathy; 6) routine health maintenance and 7) social
and emotional well being. Ideally patients with DMD should be
followed in a comprehensive multidisciplinary neuromuscular
clinic in order to minimize the need for patients and families to
make multiple visits to various subspecialty clinics. Currently,
no Canadian guidelines exist for the care or surveillance of DMD
patients. As a result, Canadian clinicians must turn to several
other sources for recommendations including: American
Academy of Neurology and Child Neurology Society (practice
parameter for corticosteroid use in DMD patients)16; American
Thoracic Society (DMD respiratory care recommendations)17,
American Academy of Pediatrics (DMD cardiac surveillance
recommendations)18 and the European TREAT-NMD (DMD
comprehensive care pathway)19.
This study was part of a collaborative effort to understand,
and ultimately improve, the standard of care for Canadian DMD
patients. It was aimed at determining the current clinical
management of DMD in paediatric neuromuscular centres across
the country in the context of the existing practice guidelines.
METHODS

A five-page questionnaire was developed by the authors for
the purpose of surveying members of the Canadian paediatric
neuromuscular group (CPNG) to determine the current standard
of care for DMD in Canada. The CPNG is a group of Canadian
clinicians (comprised of child neurologists, physiatrists,
developmental paediatricians and consultant paediatricians) who
have an interest and expertise in caring for children with
neuromuscular disorders. All CPNG physicians have a
professional affiliation with a tertiary care paediatric hospital or
rehabilitation centre. The CPNG first met in 2005, and currently
meets twice each year to discuss issues pertaining to patient
advocacy and education, current clinical trials, and future
research opportunities.
Ethics approval was obtained by the University of Calgary,
Conjoint Health Research and Ethics Board (institution of JKM,
senior author). The questionnaire contained items summarized
into seven main categories pertaining to the care of DMD
patients. The 17 CPNG members were mailed a copy of the
questionnaire. Members who did not return the questionnaire
after two months were contacted twice as a reminder.

RESULTS

Respondents

Completed questionnaires were returned by 14/17 (82%) of
physicians. Twelve respondents indicated that they followed
DMD patients. These respondents completed all portions of the
questionnaire. All regions of Canada were represented among
respondents, including western Canada (5), Ontario (7), Québec
(1) and eastern Canada (1). Physicians following DMD patients
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described their scope of practice as child neurology (8/12),
physical medicine and rehabilitation (3/12) or developmental
paediatrics (1/12). The mean length of time in practice was 17.8
yrs (range: 4 - 41 yrs).
1. Multidisciplinary teams

All respondents (12/12) followed DMD patients in a
multidisciplinary care setting. Multidisciplinary teams were
comprised of: respirology (11/12), neurology or physiatry
(11/12), social work (10/12), clinic nurse (9/12), occupational
therapy (9/12), physiotherapy (9/12), orthopaedic surgery (7/12),
cardiology (4/12), general paediatrics (4/12) and/or dietician
(3/12). Five respondents followed only paediatric DMD patients
(<18yrs old) while seven followed both paediatric and adult
DMD patients.
2. DMD diagnosis

Genetic testing for dystrophin gene deletions or duplications
is the initial diagnostic test ordered at all centres for males
presenting with suspected DMD. Centres indicated that they may
order 1) multiplex polymerase chain reaction with florescent insitu hybridization probes, or 2) multiple ligation-dependent
probe amplification. Complete DMD gene sequencing is used at
some centres if initial genetic testing is negative.
Muscle biopsy is performed at 11/12 centres when genetic
testing fails to detect a dystrophin gene mutation in a clinically
symptomatic male. Genetic counselling was routinely offered at
all centres with the aim of: 1) identifying asymptomatic female
carriers to facilitate cardiac surveillance, and 2) providing
counselling regarding recurrence risk for immediate and
extended family members.
3. Corticosteroids

Deflazacort (0.9mg/kg/d) was used at all centres. Two
respondents indicated that they occasionally used prednisone
(0.75mg/kg/d) for treatment of some patients. Respondents
indicated some variability with regard to the start of
corticosteroid therapy. Most centres used patient’s age as a
criteria for initiating treatment, around three to five years (3/12)
or six to eight years (4/12) of age. No centre routinely started
corticosteroid therapy after eight-years-old. One centre initiated
treatment at the time of DMD diagnosis. Others (3/12) used
qualitative functional assessment (i.e. “increased gait difficulties
and falling”) as a means for treatment initiation. One respondent
indicated that treatment was initiated after “discussion with
caregiver” at any of the age intervals listed above. Corticosteroid
therapy was continued indefinitely by most clinicians (11/12),
even after patients became unable to ambulate independently.
Calcium and vitamin D supplementation were routinely
recommended at most centres (10/12) when DMD patients
started corticosteroid therapy. The dose of recommended
calcium supplementation varied from 600-1200 mg/day and
vitamin D 200-1000 IU/day. One respondent recommended oral
creatine and salbutamol routinely. Whey protein supplements
were recommended at another centre.
Routine bone densitometry (DEXA scan; dual energy X-ray
absorptiometry) was offered at 10/12 centres. These centres
obtained baseline DEXA scans prior to starting corticosteroid
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therapy with surveillance scans completed at 6-24 month
intervals. One centre indicated that inadequate resources
precluded their ability to obtain bone densitometry. If bone
demineralization was identified, 6/12 respondents indicated they
would consult endocrinology for possible bisphosphonate
therapy (alendronate, pamidronate or zoledronate). Several
clinicians (3/12) indicated they would manage bisphosphonate
administration independently.
4. Orthopaedics

Respondents indicated that orthopaedic surgery was part of
over half (7/12) of all multidisciplinary teams. Teams without
orthopaedics had either physiatry (3/12), combined physical and
occupational therapy (1/12) or physiotherapy alone (1/12) to
monitor and treat soft-tissue contractures, assess mobilization
and monitor for scoliosis. Overall, allied health members were
well represented on most multidisciplinary teams with
physiotherapy (9/12) and occupational therapy (9/12) being the
most common.
Night splints were routinely offered at all centres (12/12).
Splints use was started between ages three to ten years for
managing fixed plantar flexion contractures from tight Achilles
tendons. Most centres (9/12) offered routine, surveillance
radiographs for scoliosis. The onset of surveillance at each centre
was not specified.
5. Respiratory

Respirology was the most consistent member of the
multidisciplinary team (11/12), reflecting the importance of the
respiratory system in this progressive muscle disease. The one
team lacking respirology indicated that they independently
monitored pulmonary function tests (PFT) and referred to
respirology when PFT abnormalities were detected.
Routine, anticipatory PFT was offered at 11/12 centres
starting between ages 6-11 years-old, and followed at 6-12
month intervals. One centre began PFT testing when DMD
patients became symptomatic for respiratory difficulties. Sleep
evaluation studies were routinely performed at 10/12 centres.
Four respondents indicated that they used age-criteria with the
time of the first study varying from 7 years old to 12-16 yearsold. Four respondents offered sleep studies when varying degree
of PFT abnormalities were detected (i.e. Forced vital capacity
(FVC) <80% predicted value or FVC <1L). Two centres indicate
that they offer routine sleep study evaluations when patients
present with symptoms of nocturnal hypoventilation (i.e. daytime somnolence, morning headaches and fatigue). Two centres
did not offer routine sleep study evaluations. Breath stacking and
cough-assist techniques (manual or mechanical) were offered at
9/12 centres.
6. Cardiac

Respondents indicated that cardiology was not typically a
member of multidisciplinary teams. Teams lacking cardiology
(8/12) indicated that cardiology referrals were initiated at the
time of initial diagnosis (6/8), when surveillance testing
indicated electrocardiogram (EKG) or echocardiogram
abnormalities (1/8) or when the child reached ten-years-old (lateambulation stage) (1/8).
Volume 37, No. 2 – March 2010
https://doi.org/10.1017/S0317167100009926 Published online by Cambridge University Press

Electrocardiogram and echocardiograms were most often
ordered and followed directly by cardiologists (10/12) whether
or not they were part of the DMD multidisciplinary team.
Studies were completed at one to two years intervals. Holter
monitoring was not part of surveillance studies at any centre and
was requested only if there was a clinical history of symptomatic
cardiac arrhythmias.
7. Health Maintenance

Pneumococcal and influenza vaccinations were routinely
recommended by 11/12 respondents. Varicella vaccination was
also commonly recommended (10/12). Registered dieticians
were routinely involved in patient care at 4/12 centres.
This questionnaire did not ask CPNG members about the
timing or details surrounding the discussion of end-of-life issues
with DMD patients and families (i.e. long-term mechanical
ventilation via tracheostomy versus palliation). All respondents
indicated that palliative care was not a routine part of the
multidisciplinary clinic team.
DISCUSSION

As evident from the survey responses, children with DMD
appeared to be receiving relatively consistent care across
Canada. Based upon the results of the questionnaire, the
following discussion will focus on the clinical practise in Canada
within the context of existing evidence and/or guidelines.

1. Multidisciplinary teams

Multidisciplinary teams provide patients with the benefit of
receiving multiple sub-specialist opinions at one clinic visit.
This has the effect of ‘stream-lining’ and optimizing patient care.
Respondents have indicated that multidisciplinary clinics are
commonplace at all Canadian paediatric tertiary care centres.
2. Duchenne muscular dystrophy diagnosis

Duchenne muscular dystrophy males may possess a
dystrophin gene with; 1) large deletion (65% cases); 2)
duplication (5-10% cases) or; 3) point mutations (25-30%
cases)20. Large deletions are readily detectable (98% cases) by
polymerase chain reaction with subsequent florescent in situ
hybridization, especially at one of two regions or “hot-spots”
(i.e. exons 2-20 and 44-53) where deletions are more likely to
occur. Large deletions at other locations, duplications and point
mutations will not be detected by this method, and require either
multiplex ligation-dependent probe amplification, muscle biopsy
or dystrophin gene sequencing for confirmation of diagnosis.
Emerging DMD treatments are becoming increasingly tailored to
genotype-specific patients (i.e. PTC124 for premature stop
codon suppression, or exon skipping using antisense
oligonucleotides) and treatment efficacy may hinge upon the
type of mutation21. Obtaining complete DMD gene sequencing
remains a time-consuming process, requiring government preapproval for out-of-province testing in all provinces except
Ontario. Fortunately, the results of this survey indicate that
Canadian clinicians are pursuing this important step when DMD
gene deletions/duplications cannot be identified.
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3) Corticosteroids

Prednisone and deflazacort are both accepted therapies
offered to boys with DMD16. Deflazacort, a synthetic derivative
of prednisolone, is not approved by Health Canada for use in
DMD patients; however, it can be obtained in this country
through a government Special Access Program. In the United
States, deflazacort lacks Food and Drug Administration (FDA)
approval and must be obtained from out-of-country suppliers.
Eight published randomized controlled trials (Table 1) have
demonstrated corticosteroids to improve DMD patient muscle
strength and timed function tests. This includes seven
randomized trials of prednisone (or prednisolone) versus
placebo1-3,22-25 and 1 deflazacort versus placebo trial9.
Several prednisone doses (0.3mg/kg; 0.75mg/kg; 1.5mg/kg)
and schedules (daily, alternate days; 10 days/month) have been
studied. Daily prednisone 0.75mg/kg/day is currently accepted
as the optimal dose, providing the best balance of therapeutic
benefit relative to the potential for steroid-related side-effects16.
Daily deflazacort at 0.9mg/kg/day is an accepted alternative to
prednisone16,19, and may offer a more favourable side-effect
profile4,5,15. There have been two randomized studies directly
comparing deflazacort to prednisone (0.75mg/kg)15,26,27, but the
reporting of these trials does not allow conclusive determination
of either drugs superiority in DMD.
Mendell et al (1989)1 provided the first, large, randomized
control of daily prednisone (0.75mg/kg and 1.5mg/kg) versus
placebo. Both high and low prednisone doses were associated
with an improvement of timed functional testing, as early as one
month after treatment onset. At six months (end-point of study),
both prednisone groups showed similar benefit to muscle
strength, function and PFT versus placebo. The higher
prednisone dose (1.5mg/kg) did not confer additional functional
benefit, but instead was associated with a higher incidence of
side effects such as cushingnoid features, hirsutism, and weight
gain. Fenichel et al (1991)3 followed these same DMD patients
for an additional six months to assess the effect of alternate-day
prednisone dosing. The former-placebo group was given
prednisone (2.5mg/kg) every other day, while the former-daily
prednisone groups (0.75mg/kg and 1.5mg/kg) were changed to
alternate-day prednisone (1.25mg/kg and 2.5mg/kg). Each group
demonstrated deterioration of muscle strength with alternate-day
treatment at six months.
Griggs et al (1991)2 provided a randomized controlled trial
comparing two lower doses of daily prednisone (0.75mg/kg and
0.3mg/kg) versus placebo. Again, both prednisone doses was
associated with improved muscle strength, function and PFT, as
early as ten days after treatment initiation. However, by three
months individuals receiving prednisone 0.75mg/kg were
significantly stronger than the 0.3mg/kg group. This study was
influential at establishing prednisone 0.75mg/kg as the
recommended treatment dose for DMD patients in the United
States16; however it is noteworthy that the 0.75mg/kg dose was
associated with a higher incidence of side-effects.
Four additional randomized, placebo-controlled studies have
demonstrated a clear therapeutic benefit to prednisone:
Beenakker et al (2005)25 studied prednisone 0.75mg/kg for first
ten days per month; Backman et al (1995)23 used daily
prednisolone 0.35mg/kg; Rahman et al24 studied daily
prednisolone 0.75mg/kg; and Griggs et al (1993)22 used daily
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prednisone 0.3mg/kg & 0.75mg/kg. All studies demonstrated
improvement in muscle strength and timed functional test in the
steroid group relative to placebo. Griggs’ study was the longest
in duration; it showed that the initial benefit seen with daily
prednisone therapy persisted at 18 months, and the addition of
azathioprine to some patients during the last 12 months of
treatment did not confer any additional benefits22.
Deflazacort has been the subject of two controlled trials
comparing to placebo. The first non-randomized trial4 compared
daily deflazacort (1mg/kg) to placebo for nine months.
Deflazacort-treated patients were stronger by three months, with
improvement in their timed Gower’s manoeuvre evident by six
months, and the differences increased by nine months. Side
effects of deflazacort included behaviour changes, increased
appetite, cushingnoid appearance and hirsutism. Excessive
weight gain (i.e. >20% of baseline) was less pronounced with
daily deflazacort (7%) relative to studies with daily prednisone,
but this data has yet to be confirmed by a large direct comparison
trial16. The second randomized trial9 provided a longer-term (24
month) evaluation of alternate day deflazacort (2mg/kg) versus
placebo. This group confirmed superior muscle strength and
functional testing in the deflazacort group (within six months)
which was sustained at 24 months. In this study, deflazacorttreated patients had an average weight gain of only 11.4%
compared to 7.5% for the placebo group.
Only two small trials have directly compared daily
deflazacort (0.9mg/kg) with daily prednisone (0.75mg/kg)15,26,27.
Bonifati et al15 reported no statistical difference in the efficacy of
the two drugs after 12 months treatment, and a trend in less
weight gain was seen with deflazacort (9% compared to 21.3%
increase with prednisone)15. The second trial was never
published beyond interim results26,27. Clearly there is a need for
a large, multi-centre trial directly comparing the therapeutic
benefit and side-effect profile of deflazacort and prednisone.
Until then, systematic reviews28, meta-analysis29 and medical
societies16 have recommended either daily prednisone
(0.75mg/kg) or deflazacort (0.9mg/kg) for maintaining muscle
strength and function for individuals with DMD.
Corticosteroids: Benefits beyond strength

There is mounting evidence that the benefit of corticosteroids
extends beyond skeletal muscle. Prednisone and deflazacort have
been shown to improve pulmonary function tests1,2,13; delay the
onset and/or decrease the incidence of cardiomyopathy10-12; and
scoliosis13,14. Biggar and his colleagues provided evidence from
both prospective13 and retrospective studies5,10, including one of
the best longitudinal prospective data on a cohort of DMD boys.
Fifty-four individuals received either daily deflazacort 0.9mg/kg
(30 patients) or no treatment (24 patients), and were followed for
a mean of 7.2yrs (treatment group) and 7.4yrs (control group).
The results showed that deflazacort-treated DMD boys had a
striking improvement in muscle strength, pulmonary function as
well as a marked reduction in the incidence of scoliosis. The
mean age that deflazacort-treated patients stopped walking was
12.3yrs (versus 9.8 yrs in controls). The deflazacort group had a
mean FVC of 72% predicted (range 50-88%) versus 35%
predicted (range: 20-48%) for controls. Scoliosis (curve >20o)
was much less common in deflazacort-treated boys (5/30, 17%)
compared to controls (16/24, 67%)13. Deflazacort-related side-
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effects in the treatment group included weight gain (mean of 3.7
kg more than control group), osteopenia and symptomatic stress
fractures (10%), and asymptomatic cataracts (33%)13.
Corticosteroids: When to initiate therapy

There are no randomized controlled trials on the optimal age
for initiating corticosteroid therapy in DMD. This lack of
information may explain the variability seen among our survey
respondents as to when steroid therapy is initiated. Most studies
have included corticosteroid use for DMD boys between 5-15
years old1-3. One small, open-label, prospective cohort study
examined younger (2-4 yrs old) DMD boys treated with
prednisone (initially 0.75mg/kg daily; x 2 weeks; then 1.25
mg/kg on alternate days). After 55 months treatment, all patients
in the prednisone group were still able to rise from the floor,
whereas 2/3 of the control patients had lost that ability30. Another
prospective uncontrolled study of six boys under five years of
age treated with intermittent prednisone (ten days per month)
reported an improvement of muscle strength and functional
testing, compared to the natural history of untreated young DMD
boys31. The sample size for these two studies was extremely
small (five to six patients each). This finding points to the need
for future studies to better delineate the optimal age for initiating
corticosteroid treatment.
Corticosteroids: When to discontinue therapy

The issue of when to discontinue corticosteroid therapy is
also controversial. Our survey found that almost all responding
Canadian neuromuscular specialists continued deflazacort
indefinitely for DMD individuals even after losing independent
ambulation. This practice may be due to the results of several
retrospective, open-labelled cohort studies indicating deflazacort
treatment to be associated with delayed onset of late
complications (listed above). Continuing corticosteroid therapy
for the potential benefit of delaying cardiomyopathy and
respiratory failure must be balanced with ongoing bone
demineralization, a serious concern for the non-ambulatory, nonweight bearing patient. The potential for substantial weight gain
and its accompanying morbidity (i.e. increased incidence of
obstructive sleep apnea, worsening hypoventilation, increased
challenge for caregivers surrounding patient transfers) are other
reasons for caution. Further prospective studies are needed to
evaluate the risk-benefit ratio of corticosteroid use in nonambulatory DMD males.
Corticosteroids & monitoring bone health

Ensuring optimal bone health with adequate calcium and
vitamin D intake is an important consideration, since
corticosteroid therapy appears to increase the risk of vertebral
fracture in DMD patients, which may occur following minor or
no identifiable trauma32. A recent DMD workshop (Cincinnati,
USA)33 acknowledged that while vitamin D and calcium
contribute to bone health, supplementation has not been proven
to reduce the risk of low-impact fractures among DMD boys.
Experts recommended that clinicians check serum 25hydroxyvitamin D levels annually and offer supplementation for
levels <20ng/mL33. In contrast, current European guidelines
recommend routine supplementation with calcium (4-8 yrs old:
Volume 37, No. 2 – March 2010
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800mg/d; 9-18 yrs old: 1300mg/d) and vitamin D (400 IU/d) if
dietary intake is inadequate19. Our survey demonstrates that most
Canadian DMD centres follow the European guidelines by
recommending vitamin D and calcium supplementation at the
initiation of steroid therapy.
Expert recommendations from another DMD workshop
(Birmingham, UK)32 recommended bone densitometry or DEXA
scan (dual energy X-ray absorptiometry) in all DMD patients at
one to two year intervals32. However, there is no consensus as to
what skeletal sites should be studied (i.e. hip, femur, lumbar
vertebrae, total body) or what Z-score threshold might trigger the
initiation of bisphosphate therapy33. Duchenne muscular
dystrophy boys have delayed growth and puberty as well as
diminished muscle mass, all of which may contribute to
potentially lower age-matched bone-density scores33. Although
most Canadian DMD centres obtain routine bone density studies
(every 6-24 months), further studies are needed to identify
reliable predictors for non-traumatic fractures in DMD
patients33.
Other therapies

Limited benefits for DMD patients has been demonstrated
with several other drugs such as creatinine monohydrate34,
salbuterol35,36 and cyclosporine37. No therapeutic benefit has
been found with use of: anabolic steroids (oxandrolone)38,
allopurinol39, glutamine40, selenium or vitamin E41. A clinical
trial of PTC124 a nonsense mutation read-through agent
(Ataluren™, PTC Therapeutics Inc., Cambridge, MA) is
currently underway for DMD and Becker Muscular Dystrophy
(BMD) boys known to have a nonsense mutation (premature
stop codon). If effective, this drug would offer benefit to only a
subgroup of DMD patients. In our study only one respondent
routinely uses creatine monohydrate and salbuterol, reflecting
the need for more studies to determine their clinical relevance.
4. Orthopaedics

Scoliosis is a common complication of DMD20,42. Most
individuals with DMD develop scoliosis with loss of
independent ambulation14. An early, natural history study of 33
DMD boys who did not receive spinal fusion, revealed their
scoliosis to progress to a mean curvature of 89.6 + 33.7º at the
time of death42. Some experts have recommended surveillance
spine radiography be conducted every six months during
adolescence43, however, no consensus guidelines exist.
Scoliosis contributes to the deterioration of respiratory function
in DMD patients, with an estimated 4% loss of forced vital
capacity for every 10º progression of the Cobb angle44. Scoliosis
surgery delays further deterioration of pulmonary function and
may improve long-term survival45. It also improves patient
comfort and facilitates sitting, transfer, and personal care.
However, scoliosis surgery may not reverse the loss of vital
capacity46.
Due to progressive weakness, DMD patients do not benefit
from non-surgical interventions such as bracing for scoliosis47.
Instead, spinal fusion is often performed at early stages (with
radiographic deformity as slight as 10-20º)48. The rate of all
operative and post-operative complications (i.e. skin infection or
pneumonia, pleural effusion, cardiac arrest, need for long-term
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ventilation and tracheostomy, hardware malfunction) in DMD
boys undergoing scoliosis surgery is approximately 10-30%48,49.
A FVC of 30-40% was once referred to as a “cut-off” for
DMD scoliosis surgery, due to increased cardiorespiratory
morbidity associated with further respiratory weakness however,
a recent retrospective study led to a revision of this thinking49.
Marsh et al49 reviewed the complications of scoliosis surgery
among 30 DMD patients with a range of FVC (18-60%).
Patients were grouped according to their pulmonary function: 17
patients had FVC >30%; 13 patients were <30%. The two groups
demonstrated no difference in complication rate, time in the
operating suite, duration of post-operative ventilator support or
duration of inpatient stay. Other studies have demonstrated
clinical benefit for scoliosis surgery in DMD patients with severe
respiratory muscle weakness, including those with FVC <30%
predicted49, although the best prognosis occurs for patients with
FVC > 40%42.
The American Thoracic Society (ATS) has stated that FVC
values alone should not represent an absolute contraindication to
scoliosis surgery17. Prior to surgery, all DMD patients should be
evaluated by a respirologist17, receive a complete cardiac
evaluation including echocardiogram even if no symptoms of
cardiac failure are clinically evident16, and have pre-operative
consultation from anaesthesiology.
5. Respiratory

Duchenne muscular dystrophy patients experience a gradual
loss of respiratory muscle strength over time. The onset of
hypoventilation and subsequent need for ventilation is associated
with loss of independent ambulation50. Patients first develop
ineffective and weak cough followed by increasing alveolar
hypoventilation and eventually respiratory failure, which is the
cause of death for roughly 90% of DMD patients20.
The ATS recommends that DMD patients should be seen by a
respirologist for anticipatory medical guidance and baseline
pulmonary function testing early in the course of their disease
(i.e. age 4-6 yrs)17. Follow-up frequency should be increased to
six monthly intervals, either: 1) beginning at 12 years-of-age, 2)
after loss of independent ambulation, or 3) after decline in
FVC<80% predicted17. Patients requiring use of mechanically
assisted airway clearance therapy or mechanically assisted
ventilation should also be seen by respirology every three to six
months.
Our survey indicated that sleep studies are not widely
performed across Canadian centres, in part related to inadequate
resources. The ATS recommends annual evaluation for sleepdisordered breathing for all DMD patients starting from the time
that they are wheelchair-bound and/or when clinically indicated.
This should include annual polysomnography or overnight pulse
oximetry with continuous CO2 monitoring17. Early detection and
treatment of nocturnal hypoventilation and CO2 retention may
improve daytime quality of life and delay the onset of pulmonary
hypertension. Nocturnal non-invasive ventilation using bi-level
positive airway pressure (BiPAP) is typically the first step in
providing respiratory support for DMD patients with
deteriorating respiratory function. The advent of non-invasive
ventilation in the 1990’s has significantly increased the life
expectancy of DMD males, with the mean life expectancy now
at 25.3 years51.
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Individuals with DMD are at increased risk of atelectasis and
subsequent pneumonia when they are no longer able to generate
a sufficient cough to clear their airways. As DMD patients are
typically unaware of this issue, cough effectiveness should be
assessed regularly by measuring maximal inspiratory and
expiratory pressures, peak cough expiratory flow, and forced
vital capacity17. Almost all Canadian centres follow pulmonary
functions routinely, with most offering cough assist and breathstacking support. Current recommendations suggest that cough
assist devices be employed for all DMD patients with peak
cough flow <270 L/min and/or maximal expiratory pressure less
than 60cm H2O17.
6. Cardiac

Nigro et al (1990)52 has provided one of the best studies
documenting the natural history of cardiac disease among DMD
patients. A group of 328 DMD patients were followed between
3-11 years. Pre-clinical cardiac involvement was reported in
25% of patients under six-years-old, increasing to 59% between
six to ten-years-old. Clinically apparent cardiomyopathy was
first noted after age ten years, and was present in all DMD
patients over 18-years-old. Cardiac failure is the cause of death
in 10-20% of DMD males50. Right ventricular failure may also
develop from respiratory failure and pulmonary hypertension.
The onset of dilated cardiomyopathy may precede clinical
signs of heart failure (i.e. chest pain, palpitations or dyspnea) by
several years. Symptoms of early cardiac failure may be more
difficult to recognize in DMD patients due to skeletal muscle
weakness and overall physical inactivity. One retrospective study
suggests that early corticosteroid therapy may have the added
benefit of delaying the onset of left ventricular (LV)
dysfunction12. Another randomized controlled trial demonstrated
a beneficial effect associated with the early, prophylactic use of
the angiotensin converting enzyme inhibitor (ACE-I)
perindopril53. The onset and subsequent progression of left
ventricle dysfunction was less in DMD boys treated with
prophylactic perindopril compared to placebo-controls53.
After echocardiogram evidence of cardiomyopathy becomes
apparent, sustained improvement in LV dysfunction has been
reported in several retrospective studies with the use of another
ACE-I (enalapril)54 or combination of an ACE-I (enalapril or
lisinopril) and a β-blocker (metoprolol or bisoprolol)55,56. The
results from these studies, however promising, must be
interpreted with caution. Data was collected retrospectively and
did not compare treatment groups to a no-treatment control or
natural history population. Furthermore, the studies did not
specify if DMD patients were previously or currently treated
with corticosteroids. Importantly, randomized, placebocontrolled trials may never be done in this area. Since ACE-I
have been demonstrated to be beneficial for the treatment of
adult non-DMD cardiomyopathy57, the withholding of these
potentially beneficial medications for a control group of DMD
boys with cardiomyopathy would be difficult to justify on moral
grounds.
Currently, the American Academy of Pediatrics (AAP)18
recommends that ACE-I, β-blocker or diuretics should be
considered when signs or symptoms of cardiac dysfunction are
identified18. Additional data will be required before routine,
early, or prophylactic ACE-I therapy be recommended. Expert
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Table 1: Published data on DMD patient care: levels of evidence (American Academy of Neurology Criteria)58
Studies

Evidence level

Corticosteroid use (DMD boys; age 5-15 yrs old):
Prednisone beneficial to muscle strength, motor function tests
Deflazacort beneficial to muscle strength, motor function tests
Prednisone (0.75mg/kg/d) & deflazacort (0.9mg/kg/d) equally effective
Deflazacort has less weight gain (versus prednisone)
Corticosteroids prolongs time of independent ambulation
Corticosteroids improve pulmonary function tests relative to placebo
Corticosteroids delay onset of cardiomyopathy
Corticosteroids delay onset of scoliosis
Calcium and vitamin D supplementation reduces bone demineralization
Bone densitometry (DEXA scan) every 1-2 yrs

7 Class I 1-3,22-25
1 Class I 9
1 Class II 4
2 Class I 15, 59
1 Class I 15
1 Class I 13
1 Class II 8; 3 Class III 5,6,10
2 Class I 1,2
1 Class II 13
3 Class III 10-12
1 Class II 13
1 Class IV 14
Expert opinion 19
Expert opinion 32

A
A
A
A
A
A
B
B
U
U

Corticosteroid use (DMD boys; age <5 yrs):
Prednisone prolongs proximal strength (ability to get up from floor)
Prednisone (intermittent) improves motor function testing

1 Class II 30
1 Class III 31

U
U

Scoliosis:
Scoliosis surgery (Cobb angle >20o) improves FVC and peak expiratory flow

1 Class II 45

B

Expert opinion 17,18
Expert opinion 17
Expert opinion 17
Expert opinion 17

U
U
U
U

Expert opinion 17
Expert opinion 18,19,50
1 Class IV 54
1 Class III 55
1 Class IV 56
1 Class I 53

U
U
U
U

Respiratory:
Respirology evaluation (inc. exam, pulmonary function test) at 4-6 yr old
Respiratory evaluation q6mos at 12yr old, when not walking, or FVC <80%
Annual polysomnography with continuous CO2 monitor or overnight oximetry
Cough-assist device should be considered if impaired airway clearance,
peak cough flow <270 L/min or max expiratory pressure <60 cm H2O
Cardiac:
Annual cardiac evaluation (exam, EKG, echo) beginning at school-age
Bi-annual cardiac evaluation until 10yrs old, annual after 10yrs old
Enalapril therapy of DMD cardiomyopathy results in sustained left ventricle function
Combined ACE-I + !-blocker therapy results in sustained left ventricle function
Early, prophylactic perindopril may delay onset & progression of
Left ventricle dysfunction
Routine holter monitoring only if cardiac dysfunction detected
Health maintenance:
Routine nutrition monitoring and /or deflazacort use may reduce
weight-gain
Routine pneumococcal, varicella, influenza vaccines (prior to steroids)

Expert opinion

18

1 Class II4
Expert opinion

A
U

C
17

U

Classification of studies:
Class I:
Evidence provided by prospective, randomized control trial with marked outcome assessment and all of:
i) primary outcome clearly defined;
ii) exclusion/inclusion criteria clearly defined;
iii) adequate account of drop-outs / crossover patients that are sufficiently low to not bias results;
iv) relevant baseline characteristics between treatment and placebo groups.
Class II:
Class III:
Class IV:

Evidence provided by prospective matched group cohort study in representative population with marked outcome
assessment that meets (i - iv, above) OR randomized control trial in representative population lacking 1 criteria (i - iv)
Evidence for all other control trials, including well-defined natural history control or patients serving as own
controls in a representative population where outcome assessment is independent of patient treatment.
Evidence for uncontrolled studies, case series, case reports or expert opinions.

Translation of evidence to recommendations:
Level A:
Establishes treatment as effective/ineffective/harmful for specified population
Requires at least 1 convincing Class I study or at least 2 Class II studies
Level B:
Establishes treatment as probably effective/ineffective/harmful for specified population
Requires at least one convincing Class II study or at least 3 consistent Class III studies
Level C:
Establishes treatment as possibly effective/ineffective/harmful for specified population
Requires at least 2 convincing & consistent Class III studies
Level U:
Data is inadequate or conflicting given current knowledge
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opinion from American and European groups recommend that all
DMD patients receive a complete cardiac assessment at
diagnosis, every two years until age ten years old, and annually
thereafter18,50. Although paediatric cardiologists are frequently
not members of Canadian DMD multidisciplinary teams, almost
all centres refer patients to cardiology at the time of initial
diagnosis. Cardiac follow-up becomes more frequent with
advancing age, when the risk of underlying cardiomyopathy
increases. Cardiology consultation may operate outside of the

team due to the need for concomitant, EKG and echocardiogram
testing that may not be easily integrated into the team visit.
Given the need for these important surveillance studies, many
Canadian centres opt to schedule cardiology visits at separate
times.
Holter monitoring is not a routine part of cardiac surveillance;
however, the AAP recommends periodic Holter monitoring for:
1) DMD patient with symptoms of possible cardiac arrhythmia
(e.g. palpitations, chest pain), or 2) DMD patients with

Table 2: Summary of suggested DMD patient management: clinical practice guidelines16-19,50
Key Stages &
Intervention
Patient / family
knowledge:

At diagnosis or early stage
(2 to 7 years old)
Discuss:
DMD natural history, genetics
Role of corticosteroids
Research studies
Genetic counselling referral
(Carrier testing if indicated)
Provide written material, websites
and peer support information
Muscular Dystrophy Canada (MDC)
contact information

Professional support

Medical consultations:
Genetics
Respirology
Orthopedics (night splints, scoliosis)
Cardiology
Neurology / Physiatry
Ophthalmology (cataracts)
Allied health support:
Clinic Nurse
Dietician
Physiotherapist
Psychologist
Occupational therapy
Social worker
MDC community liaison

Medical therapy:

Immunizations:
Varicella vaccine
Pneumococcal vaccine
Influenza vaccine
Corticosteroids
Deflazacort (0.9mg/kg/d) or
Prednisone (0.75mg/kg/d)
Physiotherapy:
Passive stretching, night splints
Bone health:
Calcium supplementation
Vitamin D supplementation

Loss of ambulation / adolescence
(8 to 16 years old)

Later stages
(>16 years old)

Discuss:
Nutrition
Complications of DMD (scoliosis,
cardiac, and respiratory)
Complications of corticosteroids
Symptoms of nocturnal hypoventilation
Options for long-term ventilation
assistance (i.e. BiPAP, CPAP)
Medical management of
cardiomyopathy (if present)
School / social supports
Respite / financial issues
Adolescent needs, quality of life issues
Review previous topics

Discuss:
Transition to adult care
Options for long-term
ventilation support

Medical consultations (as before, plus)
Endocrinology (osteoporosis,
bisphosphonate therapy)

Medical consultations (as before)

Nutritional support (G-tube)
End-of-life counseling and
advance medical directive
Review previous topics

Teach:
Chest physiotherapy to family
Breath stacking, cough assist
Seating for wheelchair
Passive & active exercises

Review previous topics

Review previous topics

Interventions (as required):
Angiotensin converting enzyme inhibitor
and/or beta-blocker (cardiomyopathy)
Diuretics (congestive heart failure)
Antibiotics (respiratory tract infections)
Sitting ankle-foot orthosis
Scoliosis surgery (pre-op Cardiology,
Respirology & Anesthesiology consults)

Other:
Behavioral intervention
Weight management
Monitoring:
Clinical:

Laboratory:

Clinical review:

Weight and height, BP monitoring
Formal muscle function, strength tests
ECG, electrocardiogram (q 2 yrs)
Pulmonary function testing
Wrist x-ray for bone age
Bone densitometry study
Urine glucose
25-hydroxyvitamin D level

Same as before, except:

Same as before, plus:
PCO2 measurement as needed

Same as before

6-12 months

3-6 months

1-3 months
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Same as before

ECG, echocardiogram (q 1 yr) >10 yr old
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significant cardiomyopathy18. A prospective, cohort study
revealed that frequent ventricular premature complexes (>6 /
hour) and/or left ventricular dysfunction were associated with an
increased risk of sudden death60. The fibrous replacement and/or
dilatation of myocardial muscle fibres have been postulated to be
the cause of ventricular tachyarrhythmia in such patients60.
Early detection and institution of medical therapy (antiarrhythmics or ACE-I) may be of potential therapeutic benefit.
Cardiac complications among female carriers

Female DMD carriers may present with muscle weakness
and/or cardiomyopathy. Dilated cardiomyopathy may be the first
and only manifestation of a DMD gene mutation in some female
carriers, as marked cardiac involvement may occur in the
absence of skeletal muscle weakness61. Serum CK is not a
reliable means of screening for potential female carriers of
mutated DMD genes, since elevated CK (2-10x normal) was
only seen in 53% females with DMD-relatives and 30% females
with BMD-relatives62.
Hoogerwaard et al (1999) also provided one of the best
prospective cohort studies of female DMD carriers; obligate
female carriers (ages 18-58 yrs old) who had male relatives
affected by either DMD (84) or BMD (43). At the time of
evaluation, most carrier females (76%) were asymptomatic,
while others reported myalgias or cramps (5%) or mild-tomoderate (9.5%) weakness on strength testing. Complete cardiac
evaluation of these women with male DMD relatives found that
8% (7/84) had echocardiogram evidence for dilated cardiomyopathy and 19% (16/84) had left ventricle dilatation. Results
for female carriers with male BMD relatives were similar, except
that echocardiogram evaluation demonstrated that none had
dilated cardiomyopathy, and 16% (7/35) had left ventricular
dilation62.
In light of female carriers having increased risk for skeletal
and cardiac muscle involvement, the AAP recommends all
female carriers to receive an initial cardiology assessment by
late-adolescence, with repeat cardiac evaluation subsequently
every five years, beginning at 25-30 years old18.
7. Health Maintenance

The ATS recommends that all DMD patients receive
pneumococcal vaccination and annual influenza vaccination17.
Our survey results are in keeping with this recommendation.
Most clinicians also advise varicella vaccination prior to
corticosteroid therapy. No randomized controlled study of
corticosteroid use in DMD patients has reported an increased
risk of infection or instances of severe infection1-4, 9,15.
Adolescent DMD patients have a higher incidence (44%) of
malnutrition or obesity63. Dramatic increase in appetite
associated with corticosteroid use results in rapid weight gain for
many DMD patients, as defined by a 10-20% increase above
baseline weight within 12 months15. Early dietary consultation
has the potential to temper the steroid-associated weight gain;
one randomized controlled trial with strict nutritional monitoring
showed no significant weight gain in deflazacort-treated boys
relative to placebo4. Many centres rely upon occupational
therapy to screen for dysfunctional swallowing. Although
occupational therapy is well suited in many instances to evaluate
the mechanics of swallowing, dietician involvement may also
Volume 37, No. 2 – March 2010
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help to eliminate or avoid certain types of foods in patients with
early swallowing dysfunction.
CONCLUSIONS

Children with DMD are receiving relatively consistent care
across Canada in multidisciplinary clinics. Duchenne muscular
dystrophy management is largely in keeping with the
recommendations with regard to corticosteroid use16 and
surveillance for cardiac and respiratory complications17,18. By
describing the current clinical practice, existing scientific
evidence and expert opinions, we hope to provide a
comprehensive context for elevating the standard of practice in
Canadian neuromuscular clinics and improve the care of DMD
patients.
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